Navigation Links
New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze by Almost Half

ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007 /PRNewswire-FirstCall/ -- Abbott and MedImmune today announced results of a new study, published in the July issue of Journal of Pediatrics, showing that treatment with Synagis(R) (palivizumab) may reduce recurrent wheezing in premature infants by almost half.

Specifically, the study showed that premature infants without chronic lung disease who received Synagis prior to the study had a 49 percent reduction in the incidence of recurrent wheezing compared to preterm infants who did not receive Synagis. The two-year study also found a 51 percent reduction in the incidence of physician-diagnosed recurrent wheezing in the Synagis group compared to untreated infants.

Wheezing is a whistling sound made by air passing through airways narrowed by inflammation or muscle spasms. Children who wheeze are frequently seen by physicians to determine the cause of their wheezing.

Synagis is a biologic therapy known as a monoclonal antibody administered monthly to premature infants to prevent serious lower respiratory tract infection caused by respiratory syncytial virus (RSV), a leading cause of viral respiratory infection among infants.

According to the World Health Organization, 64 million people are infected with RSV each year, and 160,000 will die from this disease. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday.

'With this new study we see that, by preventing the most serious forms of RSV infections from progressing to its most serious form, Synagis may help protect premature children without chronic lung disease from recurrent wheezing in the first few years of life,' said Eric Simoes, MD, professor, Department of Pediatric Infectious Diseases, University of Colorado School of Medicine and lead investigator in the study.

RSV infection usually manifests as an upper respiratory tract infection with symptoms resembling a cold. In preterm infants, however, the infection has an increased risk of progressing to a lower respiratory tract infection that sometimes requires hospitalization, mechanical ventilation and intensive care. Beyond the acute consequences of infection, epidemiologic data suggest a link between early RSV-associated hospitalization and chronic respiratory complications, such as recurrent wheezing and asthma, which may extend into adolescence.

Synagis, when administered to preterm infants as RSV prophylaxis, has previously shown a 55 percent reduction in hospitalizations due to RSV. Researchers in the current study hypothesized that Synagis, by preventing serious RSV disease, may be responsible for a reduction in recurrent wheezing later in life.

Clinical Trial Design

The study published today was conducted at 27 locations in Spain, Germany, The Netherlands, Canada, Poland and Sweden. Researchers prospectively followed a group of preterm infants (born <35 weeks gestational age) who received at least three doses of Synagis for RSV prophylaxis during their first year of life, and a matched group of preterm infants not treated with Synagis. The Synagis group consisted of 191 preterm infants who were less than 36 months of age and who were not hospitalized for RSV. The control group included 230 preterm children who were matched by chronologic and gestational age: 76 had been hospitalized for RSV and 154 had not. Study subjects were followed for 24 months beginning at a mean age of 19 months.

The primary endpoint of the study was the incidence of recurrent wheezing, defined as three or more episodes of wheezing in the preceding 12 months. An episode of wheezing was defined as one or more consecutive days of wheezing, preceded and f ollowed by a healthy period of at least one week. The study also evaluated the incidence of physician-diagnosed recurrent wheezing, defined as three or more episodes of wheezing in the prior 12 months, as verified by a physician at a physician's office, emergency room or hospital.

Clinical Trial Results

After following these infants for two years, the results showed the following key findings:

The incidence of recurrent wheezing was 49 percent lower among children who received Synagis compared to those who did not (13 percent vs. 26 percent, p=0.001). There was also significantly less physician-diagnosed recurrent wheezing in the group that received Synagis (8 percent vs. 16 percent, p=0.011).

In addition, infants who received Synagis had a significantly longer time to onset of both recurrent wheezing and physician-diagnosed recurrent wheezing, compared with the combined non-prophylaxed group.

About Synagis

Synagis is the only monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.

Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Abbott has exclusive rights to Synagis in markets outside the United Stat es. MedImmune promotes Synagis in the United States.

Important Safety Information

Globally, prescribing information varies; refer to the individual country product label for complete information. For U.S. safety information, visit Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) severe acute hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least 1 percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's Web site at

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site, at

CONTACT: international media, Annamaria Pastore of Abbott,+1-847-937-9794; or U.S. media, Kate Barrett of MedImmune, +1-301-398-4320;or financial, John Thomas of Abbott, +1-847-938-2655; or Peter Vozzo ofMedImmune, +1-301-398-4358

Web site:

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: ...
Breaking Medicine News(10 mins):